Abstract
Interest in new methods of potentiating the immune response against vaccine antigens has increased considerably over the past decade. In part, this interest is in response to vaccine initiatives that have established aggressive goals for improving existing vaccines and for developing much-needed new vaccines. Many of the candidate vaccine antigens being developed as part of this effort are synthetic or recombinant subunit structures that are often poorly immunogenic and as such, are unable to elicit protective immune responses in the absence of an adjuvant. Fortunately, our understanding of disease pathogenesis and the immunological mechanisms of protection have increased considerably over the past few years, thus providing an improved rational basis for the development of new adjuvants.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Qureshi, N., Mascagni, P., Ribi, E., and Takayama, K. (1985) Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595: Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem. 260, 5271–5278.
Myers, K. R., Truchot, A. T., Ward, J., Hudson, Y., and Ulrich, J. T. (1990) A critical determinant of lipid A endotoxic activity, in Cellular and Molecular Aspects of Endotoxin Reactions (Nowotny, A., Spitzer, J. J., and Ziegler, E. J., eds.), Elsevier Science, Amsterdam, pp. 145–156.
Ulrich, J. T. and Myers, K. R. (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J. eds.), Plenum, New York, pp.495–524.
Johnson, A. G. (1964) Adjuvant action of bacterial endotoxins on the primary antibody response, in Bacterial Endotoxins (Landy, M. and Braun, W., eds.), Rutgers University Press, New Brunswick, NJ, pp. 252–262.
Munoz, J. (1964) Effects of vacteria and bacteria products on antibody response, in Advances in Immunology (Dixon, F. J. and Kunkel, H. G., eds.), Academic, New York, pp. 397–440.
Gustafson, G. L. and Rhodes, M. J. (1992) Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143, 483–488.
Takayama, K., Din, Z. Z., Mukerjee, P., Cooke, P. H., and Kirkland, T. N. (1990) Physicochemical properties of the lipopolysaccharide unit that activates B lymphocytes. J. Biol. Chem. 265, 14,023–14,029.
Ribi, E., Cantrell, J. L., Takayama, K., Ribi, H. O., Myers, K. R., and Qureshi, N. (1986) Modulation of humoral and cell-mediated immune responses by a structurally established nontoxic lipid A, in Immunobiology and Immuno-pharmacololgy of Bacterial Endotoxins (Szentivanyi, A. and Friedman, H., eds.), Plenum, New York, pp. 407–419.
Schneerson, R., Fattom, A., Szu, S. C., Bryla, D., Ulrich, J. T., Rudbach, J. A., et al. (1991) Evaluation of monophosphoryl lipid A (MPL) as an adjuvant: Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL. J. Immunol. 147, 2136–2140.
Devi, S. J. N., Schneerson, R., Egan, W., Ulrich, T., Bryla, D., Robbins, J. B., and Bennett, J. E. (1991) Cryptococcus neoformans Serotype A glucuronoxylomannanprotein conjugate vaccines: Synthesis, characterization, and immunogenicity. Infect. Immun. 59, 3700–3707.
Meyer, T. J., Ribi, E. E., Azuma, I., and Zbar, B. (1974) Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J. Natl. Cancer Inst. 52, 103–111.
Granger, D. L., Yamamoto, K. I., and Ribi, E. E. (1976) Delayed hypersensitivity and granulomatous response after immunization with protein antigens associated with a mycobacterial glycolipid and oil droplets. J. Immunol. 116, 482–488.
Vosika, G. J., Schmidtke, J. R., Goldman, A., Parker, R., Ribi, E. E., and Gray, G. R. (1980) Phase 1 study of intradermal immunotherapy with oil-attached Mycobacterium smegmatis cell wall skeleton and trehalose dimycolate. Cancer Immunol. Immunother. 7, 221–224.
Bekierkunst, A., Levij, I. S., Yarkoni, E., Vilkas, E., Adam, A., and Lederer, E. (1969) Granuloma formation induced in mice by chemically defined mycobacterial fractions. J. Bacteriol. 100, 95–102.
Yarkoni, E., Rapp, H. J., and Zbar, B. (1977) Immunotherapy of a guinea pig hepatoma with ultrasonically prepared mycobacterial vaccines. Cancer Immunol. Immunother. 2, 143–146.
Bomford, R., Stapleton, M., Winsor, S., McKnight, A., and Andronova, T. (1992) The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res. Hum. Retroviruses 8, 1765–1771.
Lidgate, D. M., Fu, R. C., Byars, N. E., Foster, L. C., and Fleitman, J. S. (1989) Formulation of vaccine adjuvant muramyldipeptides. 3. Processing optimization, characterization, and bioactivity of an emulsion vehicle. Pharm. Res. 6, 748–752.
Ott, G., Barchfeld, G. L., and Van Nest, G. (1995) Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13, 1557–1562.
Traquina, P., Morandi, M., Contorni, M., and Van Nest, G. (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. 174, 1168–1175.
Thoelen, S., Van Damme, P., Mathei, C., Leroux-Roels, G., Desombere, I., Safary, A., et al. (1998) Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16, 708–714.
Schirmbeck, R., Deml, L., Melber, K., Wolf, H., Wagner, R., and Reimann, J. (1995) Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine 13, 857–865.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Terry Ulrich, J. (2000). MPL® Immunostimulant: Adjuvant Formulations . In: O’Hagan, D.T. (eds) Vaccine Adjuvants. Methods in Molecular Medicine™, vol 42. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-083-7:273
Download citation
DOI: https://doi.org/10.1385/1-59259-083-7:273
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-735-9
Online ISBN: 978-1-59259-083-4
eBook Packages: Springer Protocols